Trial · NCT04425629
Results by group367
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 367
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) - [Ph1, Ph2, Ph3 Cohort 1 - Cohort 3] | Combined Phases 1, 2, & 3 Cohort 1 Symptomatic (Placebo) | 97 | Participants | ||
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) - [Ph1, Ph2, Ph3 Cohort 1 - Cohort 3] | Combined Phases 1, 2, & 3 Cohort 1 Symptomatic (2.4 IV) | 31 | Participants | ||
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) - [Ph1, Ph2, Ph3 Cohort 1 - Cohort 3] | Combined Phases 1, 2, & 3 Cohort 1 Symptomatic (8.0 IV) | 19 | Participants | ||
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) - [Ph1, Ph2, Ph3 Cohort 1 - Cohort 3] | Phase 2 Asymptomatic (Placebo) | 0 | Participants | ||
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) - [Ph1, Ph2, Ph3 Cohort 1 - Cohort 3] | Phase 2 Asymptomatic (2.4g IV) | 0 | Participants | ||
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) - [Ph1, Ph2, Ph3 Cohort 1 - Cohort 3] | Phase 2 Asymptomatic (8.0g IV) | 0 | Participants | ||
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) - [Ph1, Ph2, Ph3 Cohort 1 - Cohort 3] | Phase 3 Cohort 1 (1.2g IV) Symptomatic | 14 | Participants | ||
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) - [Ph1, Ph2, Ph3 Cohort 1 - Cohort 3] | Phase 3 Cohort 2 Pediatric (Placebo) | 0 | Participants | ||
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) - [Ph1, Ph2, Ph3 Cohort 1 - Cohort 3] | Phase 3 Cohort 2 Pediatric (1.2g IV) | 2 | Participants | ||
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) - [Ph1, Ph2, Ph3 Cohort 1 - Cohort 3] | Phase 3 Cohort 2 Pediatric (2.4g IV) | 0 | Participants | ||
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) - [Ph1, Ph2, Ph3 Cohort 1 - Cohort 3] | Phase 3 Cohort 3 Pregnant (Placebo) | 0 | Participants | ||
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) - [Ph1, Ph2, Ph3 Cohort 1 - Cohort 3] | Phase 3 Cohort 3 Pregnant (1.2g IV) | 2 | Participants | ||
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) - [Ph1, Ph2, Ph3 Cohort 1 - Cohort 3] | Phase 3 Cohort 3 Pregnant (2.4g IV) | 2 | Participants | ||
| Number of Participants With Infusion-related Reactions (Ph1, Ph2, Ph3 Cohort 1 - Cohort 3) | Combined Phases 1, 2, & 3 Cohort 1 Symptomatic (Placebo) | 2 | Participants | ||
| Number of Participants With Infusion-related Reactions (Ph1, Ph2, Ph3 Cohort 1 - Cohort 3) | Combined Phases 1, 2, & 3 Cohort 1 Symptomatic (2.4g IV) | 4 | Participants | ||
| Number of Participants With Infusion-related Reactions (Ph1, Ph2, Ph3 Cohort 1 - Cohort 3) | Combined Phases 1,2, & 3 Cohort 1 Symptomatic (8.0g IV) | 7 | Participants | ||
| Number of Participants With Infusion-related Reactions (Ph1, Ph2, Ph3 Cohort 1 - Cohort 3) | Phase 2 Asymptomatic (Placebo) | 0 | Participants | ||
| Number of Participants With Infusion-related Reactions (Ph1, Ph2, Ph3 Cohort 1 - Cohort 3) | Phase 2 Asymptomatic (2.4g IV) | 0 | Participants | ||
| Number of Participants With Infusion-related Reactions (Ph1, Ph2, Ph3 Cohort 1 - Cohort 3) | Phase 2 Asymptomatic (8.0g IV) | 0 | Participants | ||
| Number of Participants With Infusion-related Reactions (Ph1, Ph2, Ph3 Cohort 1 - Cohort 3) | Phase 3 Cohort 1 (1.2g IV) Symptomatic | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04425629/results